StockDuty ← Dashboard Nov 12, 2026 10:48 PM ET
SignalEarnings

$ARWR (ARROWHEAD PHARMACEUTICALS) — 8-K: ARWR Q4 FY2026: Revenue $451M (-45.6% YoY), Net Loss $724M as R&D and PRV Costs Weigh

ARWR
$47.78
+1.34%
Arrowhead reported Q4 FY2026 revenue of $451M, down 45.6% YoY from $829M. Net loss was $724M, driven by total operating expenses of $1.16B, including $739M in R&D and a $215M acquired Priority Review Voucher charge.
Arrowhead reported Q4 FY2026 revenue of $451M, down 45.6% YoY from $829M. Net loss was $724M, driven by total operating expenses of $1.16B, including $739M in R&D and a $215M acquired Priority Review
Sources